ProfileGDS5678 / 1449402_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 64% 59% 58% 58% 59% 57% 56% 58% 68% 71% 64% 66% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6155660
GSM967853U87-EV human glioblastoma xenograft - Control 23.7994664
GSM967854U87-EV human glioblastoma xenograft - Control 33.5539959
GSM967855U87-EV human glioblastoma xenograft - Control 43.4596458
GSM967856U87-EV human glioblastoma xenograft - Control 53.4658458
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6367759
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5481657
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.418856
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4922358
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1852568
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4191271
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8035964
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9624566
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2125869